Incyte Corporation research snapshot
INCY AI stock analysis currently reads Incyte Corporation as a profitable specialty biopharma company with a strong Jakafi base, faster growth from Opzelura and newer hematology and oncology products, and a net cash balance sheet that supports pipeline investment. At the July 8, 2026 data cutoff, INCY traded near $118.05 with a verified market value near $23.58 billion. The stock has positive momentum, but the AI stock forecast remains scenario-based because future value depends on Jakafi durability, Opzelura uptake, late-stage clinical execution, regulatory timing, and capital allocation after the Vega acquisition. This page is informational research, not investment advice.
Current price
$118.05
Market cap
$23.58 billion verified market cap
AI score
69 / 100
Rating
Profitable specialty biopharma with Jakafi cash flow, Opzelura growth, and pipeline concentration risk
Trend status
Bullish but extended technical setup above the 50-day and 200-day moving averages
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Incyte sells approved medicines in hematology, oncology, and inflammation, with high gross margins, strong free cash flow, and Q1 2026 net sales growth of 20%. | High |
| Moat | The moat comes from approved indications, clinical evidence, prescriber familiarity, reimbursement access, manufacturing quality, and internal discovery capabilities, but it is narrower than a diversified large pharma moat. | Medium |
| Management | CEO Bill Meury brings commercial and deal experience, and the board uses ownership guidelines, but the next test is whether Vega and late-stage pipeline spending earn returns above their cost. | Medium |
| Financial trend | FY2025 revenue rose 21% to $5.14 billion, net income reached $1.29 billion, and Q1 2026 revenue rose 21% to $1.27 billion. | High |
| Valuation | At $118.05, audited math shows about 16.7x TTM EPS, 16.3x TTM free cash flow per share, 4.2x book value, and a 6.1% free cash flow yield. | Medium-high |
| Technical trend | The stock traded above the 50-day and 200-day moving averages, while RSI near 70 suggested strong momentum with some overbought risk. | Medium |
| Risk level | Key risks are Jakafi concentration, patent and pricing pressure, Opzelura growth expectations, clinical trial setbacks, FDA timing, and acquisition integration or write-off risk. | Medium-high |
| AI confidence | Descriptive confidence is high because the public data set is rich. Forecast confidence is medium because drug-specific events can reset sales expectations and multiples. | High data confidence |
| Investment certainty | Investment certainty is medium. The balance sheet and cash flow are strong, but the current price already discounts a meaningful amount of pipeline and launch success. | Medium |
INCY AI stock forecast
The INCY AI stock forecast uses scenario math around the $118.05 cutoff price and TTM EPS of $7.08. The audited three-year model produced valuation anchors near $179 in the bullish case, $126.5 in the base case, and $66.8 in the bearish case. These ranges are not price promises. They are a way to frame what must happen for upside, base, or downside outcomes to become more likely.
$165 to $185
More likely if Jakafi stays durable, Opzelura continues double-digit growth, Niktimvo and oncology products scale, povorcitinib and Jakafi XR approvals arrive on time, VGA039 keeps credible late-stage value, and investors pay about 18x earnings.
$120 to $135
More likely if revenue grows at a mid-single-digit to high-single-digit rate, R&D spend remains heavy but productive, Opzelura offsets slower Jakafi growth, and the market values Incyte near a mid-teens earnings multiple.
$60 to $75
More likely if Jakafi erosion arrives faster than expected, Opzelura underperforms, FDA or trial events disappoint, the Vega acquisition creates a large charge without commercial confidence, or the multiple compresses toward low-teens earnings.
INCY AI technical analysis
INCY AI technical analysis is constructive but extended as of the July 8, 2026 cutoff. StockAnalysis listed INCY at $118.05 after the July 7 close, with the 50-day moving average at $101.53, the 200-day moving average at $98.26, RSI at 70.17, and average 20-day volume near 2.19 million shares. Investing.com separately listed a 50-day moving average of $114.89, a 200-day moving average of $104.84, RSI of 62.218, and a daily Strong Buy indicator summary. The signal is positive, but source timestamps differ.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $118.05 | StockAnalysis quote snapshot after the July 7, 2026 close used for market-cap and valuation math. |
| Near support | $114 to $115 | Investing.com listed the 50-day moving average near $114.89, making this a short-term trend reference. |
| Secondary support | $101 to $105 | StockAnalysis listed the 50-day moving average at $101.53, while Investing.com listed the 200-day moving average at $104.84. |
| Long-term trend reference | $98 to $105 | StockAnalysis listed the 200-day moving average at $98.26. Investing.com listed the 200-day average at $104.84, so live chart confirmation matters. |
| Resistance | $118 to $120, then fresh highs | The stock was trading near the upper end of the recent range at the cutoff. A clean breakout needs volume support and no negative product or regulatory news. |
| Momentum | RSI 62.218 to 70.17 | Investing.com showed RSI in a buy zone, while StockAnalysis showed RSI near the overbought threshold. Momentum is strong but less attractive for late entries. |
| Volume | 2.19 million average 20-day shares | Volume should be interpreted around earnings, FDA decisions, trial data, patent news, and Vega acquisition updates. |
| Volatility | Beta 0.76, event-sensitive biotech risk | StockAnalysis listed beta below one, but biotech-specific events can still create large single-stock moves. |
| Invalidation | Close below $114, then below $101 | A break below the shorter moving-average zone would weaken swing momentum. A sustained break below the lower support cluster would require a fuller thesis review. |
INCY AI trading strategy
The INCY AI trading strategy below is a rules-based framework for a profitable biopharma stock with product concentration, strong cash generation, net cash, and regulatory or clinical catalysts. It is not personal advice and should be paired with live quotes, filings, FDA calendars, position sizing, and risk controls.
Watch for INCY to hold above the $114 to $115 short-term trend area and break cleanly above $120 with confirming volume, stable Jakafi commentary, and no negative Opzelura, FDA, trial, or Vega news.
A close below $114 should reduce swing confidence. A close below the $101 to $105 support cluster should trigger a full review of both chart momentum and the fundamental setup.
If INCY pulls back toward the $101 to $105 area without a new product, patent, clinical, or guidance problem, compare the reset price with TTM EPS, free cash flow yield, cash per share, and the audited base scenario.
Do not treat every pullback as a bargain. Product-specific bad news can turn a technical reset into a fundamental break.
Track Jakafi paid demand, Opzelura prescription demand, Niktimvo uptake, Monjuvi and Zynyz progress, povorcitinib regulatory milestones, VGA039 trial progress, R&D intensity, cash balance, and buyback or acquisition choices.
Lower confidence if earnings growth depends mainly on multiple expansion or one-time items rather than durable product growth and pipeline conversion.
Investment research summary
Incyte converts drug discovery, clinical development, regulatory approvals, and specialty commercial execution into recurring medicine revenue for serious hematology, oncology, and inflammatory diseases.
The moat is based on approved labels, physician trust, payer access, clinical data, manufacturing quality, and know-how in JAK biology and hematology. It weakens if exclusivity fades, rivals show better efficacy or safety, or payers force price concessions.
The thesis fails if Jakafi concentration proves larger than new product growth, Opzelura misses adoption expectations, late-stage programs disappoint, regulatory decisions slip, or acquisitions consume cash without creating durable earnings power.
Bill Meury joined as CEO in 2025 with commercial and deal experience. The board has equity ownership guidelines, but capital allocation should be judged by pipeline returns, launch execution, cash discipline, and whether the Vega transaction expands the hematology moat.
Specialty biopharma benefits from aging populations, immunology demand, hematology innovation, targeted oncology, and rare disease development. The same industry faces patent cliffs, payer pressure, trial failure, FDA timing, and policy scrutiny.
INCY is not priced like a distressed biotech after its rally. Margin of safety depends on whether free cash flow remains durable, the pipeline converts into approved products, and the current valuation leaves room for event risk.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| INCY quote reference | $118.05 close on July 7, 2026 | StockAnalysis INCY statistics | July 8, 2026 |
| Market capitalization verification | $23.58 billion, verified as $118.05 x about 199.78 million shares | Pineify financial_rigor.py and StockAnalysis share data | July 8, 2026 |
| Shares outstanding | 199.78 million shares outstanding | StockAnalysis INCY statistics | July 8, 2026 |
| FY2025 revenue | $5.14 billion total revenue, up 21% compared with fiscal 2024 | Incyte FY2025 financial results and SEC exhibit | July 8, 2026 |
| FY2025 net income | $1.287 billion net income, cross-validated with StockAnalysis and Macrotrends | StockAnalysis INCY income statement | July 8, 2026 |
| Q1 2026 revenue and net sales | $1.27 billion total revenue and $1.10 billion total net sales, up 21% and 20% | Incyte Q1 2026 financial results | July 8, 2026 |
| Q1 2026 product mix | Jakafi $758 million, Opzelura $143 million, hematology and oncology portfolio $204 million | Incyte Q1 2026 financial results | July 8, 2026 |
| Cash and marketable securities | $4.0 billion at March 31, 2026, cross-validated to $4.016 billion on StockAnalysis | Incyte Q1 2026 release and StockAnalysis balance sheet | July 8, 2026 |
| Debt and net cash | $39.43 million total debt and $3.98 billion net cash | StockAnalysis INCY statistics | July 8, 2026 |
| TTM valuation math | 16.67x PE, 4.20x PB, 16.26x P/FCF, and 6.15% FCF yield from financial_rigor.py | Pineify financial_rigor.py using StockAnalysis inputs | July 8, 2026 |
| Technical snapshot | 50-day moving average $101.53, 200-day moving average $98.26, RSI 70.17, beta 0.76 | StockAnalysis INCY statistics | July 8, 2026 |
| Alternative technical snapshot | Daily technicals Strong Buy, 14-day RSI 62.218, 50-day average $114.89, 200-day average $104.84 | Investing.com INCY technical analysis | July 8, 2026 |
| Management and incentives | CEO Bill Meury joined in June 2025, and the proxy lists CEO equity ownership guidelines at 6x annual base salary | Incyte 2026 proxy statement | July 8, 2026 |
| Vega acquisition | $1.25 billion upfront acquisition of Vega Therapeutics plus up to $750 million in sales milestones | Incyte Vega acquisition release | July 8, 2026 |
This INCY AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of July 8, 2026 and can be wrong if earnings, clinical data, regulatory decisions, payer policy, patent events, market multiples, or company execution change.
